Composition for inducing cancer in animal model and application thereof
By inducing animal models using sugar and acid compositions, the problem of difficult to simulate human diseases in the prior art is solved, and an accurate animal model for multiple diseases is realized, providing a theoretical basis for drug screening and treatment, and simulating humans The etiology pathways in normal diet life have achieved the induction and research of diseases.
Patent Information
- Application Number
- CN202410872748.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-02-05
- Filing Date
- 2022-01-28
- Publication Date
- 2024-11-19
AI Technical Summary
The existing technology is difficult to effectively simulate the various disease models generated by humans in normal dietary life, which leads to challenges in drug screening and treatment, especially for major diseases such as cancer, cardiovascular and cerebrovascular diseases and diabetes, and lacks effective etiology research and treatment methods. .
Provided is a composition composed of sugar and acid, which is used to induce animal models, simulate human diseases, and is used for drug screening and treatment, including the use of compositions such as glucose, acetic acid, lactic acid, phosphoric acid, etc., by feeding Feeding, gavage, intravenous infusion and other routes were applied to model animals to induce animal models such as cancer, diabetes, and cardiovascular and cerebrovascular diseases.
A precise animal model for a variety of human diseases is realized, providing a theoretical basis for drug screening and treatment, and can induce tumor tissue formation within 96 hours. It is suitable for the research and treatment of various diseases, without requiring other chemicals, simulation The path of cause in normal diet and life of humans.
Smart Images

Figure BDA0004922100630000091 
Figure BDA0004922100630000092 
Figure BDA0004922100630000101
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of life sciences and relates to a composition and application thereof. Background Art
[0002] Human beings' understanding of diseases is constantly improving with the development of society and the progress of science and technology. At present, many major diseases and chronic diseases are almost difficult to cure. Most of these diseases can only be maintained, alleviated, and controlled to develop slowly. From a global perspective, cancer, cardiovascular and cerebrovascular diseases, diabetes, etc. are the most common diseases with the highest mortality rate besides infectious diseases. Medical and scientific researchers are actively working to break through existing technologies, looking forward to the early realization of a complete and thorough solution to these major diseases and chronic diseases that endanger human life. In the past 100 years, although the research and understanding of various diseases have been continuously improved, the main key problems have not been solved. If the cause cannot be found, only symptomatic treatment can be given. If the cause path is started, it will be solved quickly. Only by clarifying the pathogenesis of the disease can the disease be effectively cured. Cancer, cardiovascular and cerebrovascular diseases, and diabetes are the most common diseases with the highest incidence in the world. With such a high probability of occurrence, we should be able to find the law to break through the cause and lay the foundation for drug screening and clinical research.
[0003] In order to meet the needs of drug screening and clinical practice, the use of accurate animal disease models that fully simulate humans' normal eating and living habits is the key to determining the success or failure of drug screening, and it also plays an important role in preventing and curing these diseases in humans. Summary of the invention
[0004] In order to solve the problems existing in the prior art, the present invention provides a composition and its use. The composition of the present invention can be made into an animal model simulating various human diseases, so as to be used for preventing and treating human diseases and screening drugs. The composition of the present invention is composed of sugar and acid / sugar, acid and alcohol, and the model animal is not limited to mammals. The composition of the present invention has great value for preventing and treating various human diseases such as diabetes, cancer, cardiovascular and cerebrovascular diseases, kidney disease, liver disease, etc.
[0005] The present invention is achieved through the following technical solutions.
[0006] In one aspect, the present invention provides a composition consisting of a sugar and an acid.
[0007] Preferably, the sugar is a polyhydroxy (2 or more) aldehyde or ketone compound composed of three elements: carbon, hydrogen and oxygen, and is preferably glucose.
[0008] Preferably, the acid is an organic acid or an inorganic acid.
[0009] Preferably, the acid is 85% (mass percent concentration) phosphoric acid, 37% (mass percent concentration) hydrochloric acid, 99.5% (mass percent concentration) acetic acid or 85% (mass percent concentration) lactic acid.
[0010] Preferably, the mass volume ratio between the sugar and the acid is 1:100-100:1 (g / mL), preferably 1:20-20:1 (g / mL), more preferably 1:0.375 (g / mL) or 5:1 (g / mL).
[0011] Preferably, the pH of the composition is below 4, preferably below 3.22;
[0012] Preferably, the composition is a food composition.
[0013] In a specific embodiment, the composition is: 1 g glucose + 0.375 ml hydrochloric acid (37% (mass percentage concentration));
[0014] A mixture of 50% (mass percent concentration) glucose injection and acetic acid (99.5% (mass percent concentration)) (volume ratio 10:1);
[0015] A mixture of 50% glucose injection and acetic acid (99.5% (mass percentage concentration)) (volume ratio 20:1);
[0016] A mixture of 50% glucose injection and lactic acid (85% (mass percentage concentration)) (volume ratio 10:1);
[0017] A mixture of 50% glucose injection and phosphoric acid (85% (mass percentage concentration)) (volume ratio 10:1). Preferably, the composition further comprises alcohol, that is, the composition consists of sugar, acid and alcohol.
[0018] Preferably, the alcohol is ethanol.
[0019] Preferably, the ratio between the sugar, acid and alcohol is 1:100:1-100:1:100 (g / mL / mL), preferably 1:20:1-20:1:20 (g / mL / mL), and more preferably 10:5:5 (g / mL / mL).
[0020] Preferably, the composition is a food composition. In the present application, the food composition simulates the food ingested by a natural person in a normal diet.
[0021] On the other hand, the present invention provides a method for preparing the above composition, which comprises mixing sugar and acid; or sugar, acid and alcohol in the above-mentioned formula ratio.
[0022] In another aspect, the present invention provides use of the above composition in preparing an animal model. For example, the composition can induce the production of cancer (eg, lung cancer), thereby serving as an inducer for preparing a cancer model.
[0023] Preferably, the model animals used in the animal model include but are not limited to mammals, such as mice, rats, rabbits, dogs, monkeys, cats, chickens, pigs, etc.
[0024] Preferably, the animal model is administered with the composition to the model animal by various routes such as feeding, oral gavage, intravenous drip, intravenous injection or skin penetration.
[0025] Preferably, the animal models include, but are not limited to, animal models of diabetes, various cancers, cardiovascular and cerebrovascular diseases caused by atherosclerosis, and other diseases.
[0026] Preferably, the animal model is used for screening drugs for preventing and / or treating cancer, diabetes, cardiovascular and cerebrovascular diseases caused by atherosclerosis and other diseases.
[0027] In another aspect, the present invention provides the use of an acid in preparing an animal model. For example, the acid can induce the production of cancer (eg, lung cancer), thereby serving as an inducer for preparing a cancer model.
[0028] Preferably, the acid is an inorganic acid (such as hydrochloric acid) or an organic acid;
[0029] Preferably, the acid is 13.88% (mass percent concentration) hydrochloric acid, 7.73% (mass percent concentration) lactic acid, 4.74-9.05% (mass percent concentration) acetic acid, 7.73% (mass percent concentration) phosphoric acid;
[0030] Preferably, the pH of the acid is below 3.22.
[0031] In a specific embodiment, the acid is:
[0032] A mixture of physiological saline and concentrated hydrochloric acid (37% (mass percentage concentration)) (volume ratio 5:3);
[0033] A mixture of normal saline and acetic acid (99.5% (mass percentage concentration)) (volume ratio 10:1);
[0034] A mixture of normal saline and lactic acid (85% (mass percentage concentration)) (volume ratio 10:1);
[0035] A mixture of normal saline and phosphoric acid (85% (mass percentage concentration)) (volume ratio 10:1);
[0036] A mixture of normal saline (10 mL) and acetic acid (99.5% (mass percent concentration)) (1 mL);
[0037] A mixture of normal saline (10 mL) and acetic acid (99.5% (mass percent concentration)) (0.5 mL);
[0038] A mixture of normal saline (10 mL) and lactic acid (85% (mass percentage concentration)) (1 mL);
[0039] A mixture of normal saline (10 mL) and phosphoric acid (85% (mass percentage concentration)) (1 mL);
[0040] A mixture of physiological saline (2.5 mL) and hydrochloric acid (37% (mass percent concentration)) (1.5 mL).
[0041] Preferably, the model animals used in the animal model include but are not limited to mammals, such as mice, rats, rabbits, dogs, monkeys, cats, chickens, pigs, etc.;
[0042] Preferably, the animal model is administered by various routes such as feeding, gavage, intravenous drip, intravenous injection or skin penetration to the model animal;
[0043] Preferably, the animal models include, but are not limited to, animal models of diabetes, various cancers, atherosclerosis and cardiovascular and cerebrovascular diseases caused by them and other diseases.
[0044] Preferably, the animal model is used for screening drugs for preventing and / or treating cancer, diabetes, atherosclerosis and cardiovascular and cerebrovascular diseases caused by them and other diseases.
[0045] Compared with the prior art, the present invention has the following beneficial technical effects:
[0046] (1) The composition of the present invention is used to prepare animal models, providing a theoretical basis for the prevention and treatment of major diseases in humans.
[0047] (2) The animal disease model prepared by the present invention completely simulates the normal eating and living habits of humans, does not require other chemical substances, and is suitable for preparing animal models of various human diseases.
[0048] (3) The composition of the present invention is an accurate animal model for screening drugs for humans and / or animals.
[0049] At present, domestic and foreign research has proved that inflammation can induce cancer. In the present invention, the sugar and acid are necessary for all animal life bodies to exist, and it is undeniable that both enter the body in addition to the normal metabolism needs of the body, and some aldehyde compounds will also be formed to attach to the cell outer membrane, when inflammation occurs in tissue, the aldehyde compounds accumulated and attached to the cell outer membrane will cause inflammation point cell necrosis when reaching the threshold value, and the aldehyde compounds after necrosis form accumulation, which aggravates cell necrosis and infiltrates normal tissue cells, and gradually forms necrosis points, nodules, small lumps, tumors. In the present invention, inflammation is seen in the puncture point, and different degrees of necrosis are also seen in the cancerous part, and multiple model pathological pictures show that the liquid injected makes tissue cells rapidly necrosis, edema, fibrous tissue hyperplasia, paracancer, cancerous tissue formation, and different degrees of necrosis are also seen in the cancerous part when cancerous tissue is formed. It is visible, and this process is generally completed in 96 hours from liquid injection to cancerous tissue formation, and then tumor tissue continues to grow, therefore, the present invention, under the joint action of multiple acids and sugar acid mixtures entering the body through puncture and injection, realizes rat and rabbit lung cancer animal model. Inflammation can occur in multiple tissues of the body, and various acids and sugar acid mixtures can enter various tissues of the body through the circulatory system after being ingested. Therefore, this model is not limited to a single lung cancer animal model, but is also a general method for making various other cancer tissue models. In other words, the various acids and sugar acid mixtures described in the present invention can be used to make all cancer animal models including leukemia.
[0050] In addition to making animal models of cancer, animal models of many other human diseases can also be made, because aldehyde compounds entering the body will reduce the permeability of cell membranes, increase transmembrane impedance, affect the normal metabolism of various cells, and cause different tissue lesions. For example, they adhere to the outer membrane of blood cells, and after blood cell necrosis, they will deposit to form thrombi, cardiovascular and cerebrovascular diseases. Adhering to the outer membrane of pancreatic islet β cells will cause insulin secretion disorders and lead to diabetes. Therefore, organic acids and inorganic acids alone or in combination with glucose can make animal models of various human diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 : Pathological staining results of control group 1 in experimental example 1 (10×10); The samples were collected after 14 days of the experiment, and the pathological results of the lung tissues of each rat were as follows: 1: no cancer, mild inflammation; 2: no cancer, hemorrhage; 3: no cancer, mild inflammation; 4: no cancer, mild inflammation; 5: no cancer, mild inflammation; 6: no cancer, mild inflammation;
[0052] Figure 2: Pathological staining results of control group 2 in experimental example 1 (10×10); The experimental plan originally planned to collect samples on the 14th day, but the rats were in poor condition after injection, and the sixth one died early. It was expected that the formula could not stably induce lung cancer in healthy rats, so the samples were collected 36 hours in advance and the experiment was terminated. The following are the results of pathological analysis of rats in this group: 1: suspected cancer; 2: no cancer; 3: no cancer; 4: no cancer; 5: no cancer;
[0053] Figure 3 : Pathological staining results of experimental group 1 in experimental example 1 (10×10); Pathological analysis results 96h (4d) after injection of the inducer were: 1: adenocarcinoma, few cancer glands; 2: adenocarcinoma, puncture point at the apex of the lung; 3: adenocarcinoma, few cancer glands; 4: adenocarcinoma, many cancer glands; 5: adenocarcinoma, many cancer glands; 6: adenocarcinoma, shallow puncture point, subpulmonary carcinoma;
[0054] Figure 4 Pathological staining results of experimental group 2 in experimental example 1 (10×10); pathological analysis results 168h (7d) after injection of the inducer: 1: adenocarcinoma; 2: adenocarcinoma; 3: adenocarcinoma; 4: adenocarcinoma; 5: suspected adenocarcinoma, the diameter of the puncture point is about 3 mm; 6: adenocarcinoma;
[0055] Figure 5 Pathological staining results of experimental group 3 in experimental example 1 (10×10); pathological analysis results 336h (14d) after injection of the inducer: 1: adenocarcinoma, granulomatous inflammation; 2: no cancer, granulomatous inflammation, superficial puncture point; 3: no cancer, puncture point 2 mm; 4: no cancer, no puncture point; 5: adenocarcinoma, mild inflammation; 6: adenocarcinoma, no clear puncture point, severe intrapulmonary hemorrhage, subpulmonary carcinoma;
[0056] Figure 6 Pathological staining results of experimental group 1 in experimental example 2 (10×10); the samples were collected after 14 days of the experiment, and the pathological detection of each lung tissue was as follows: 1: no cancer, moderate inflammation; 2: no cancer, mild inflammation; 3: no cancer, mild inflammation; 4: no cancer, mild inflammation; 5: no cancer, mild inflammation;
[0057] Figure 7 Pathological staining results of experimental group 2 in experimental example 2 (10×10); samples were collected 7 days after the experiment, and the pathological examination of each lung tissue was as follows: 1: adenocarcinoma; 2: adenocarcinoma; 3: adenocarcinoma; 4: adenocarcinoma; 5: adenocarcinoma;
[0058] Figure 8 Pathological staining results of experimental group 3 in experimental example 2 (10×10); the samples were collected 7 days later, and the pathological examination of each lung tissue was as follows: 1: about 12 hours after death, no sample was collected in time; 2: adenocarcinoma; 3: adenocarcinoma; 4: no cancer was found, and atypical hyperplasia of alveolar epithelium was found around the puncture point; 5: adenocarcinoma;
[0059] Fig. 9 Pathological staining results of test group 4 in experimental example 2 (10×10); samples were collected 7 days after the experiment, and the pathological examination of each lung tissue was as follows: 1: adenocarcinoma; 2: adenocarcinoma; 3: adenocarcinoma; 4: adenocarcinoma; 5: no cancer, inflammatory secretions in the bronchial cavity, severe inflammation;
[0060] Fig.10 Pathological staining results of experimental group 5 in experimental example 2 (10×10); the samples were collected 7 days after the experiment, and the pathological examination of each lung tissue was as follows: 1: adenocarcinoma; 2: adenocarcinoma, tumor necrosis with multinucleated giant cell reaction; 3: no cancer, severe inflammation; 4: no cancer, mild inflammation without clear puncture point; 5: adenocarcinoma, tumor cell necrosis;
[0061] Fig.11 Pathological staining results of test group 6 in experimental example 2 (10×10); the samples were collected 7 days later, and the pathological examination of each lung tissue was as follows: 1: adenocarcinoma; 2: no cancer was found, no puncture point was found; 3: adenocarcinoma; 4: died about 16 hours ago and the sample was not collected in time; 5: adenocarcinoma;
[0062] Fig.12 Pathological staining results of test group 7 in experimental example 2 (10×10); the samples were collected 7 days after the experiment, and the pathological examination of each lung tissue was as follows: 1: no cancer, clear puncture point (death at 46 hours); 2: no cancer, mild inflammation; 3: adenocarcinoma; 4: adenocarcinoma; 5: adenocarcinoma;
[0063] Fig.13 Pathological staining results of test group 8 in experimental example 2 (10×10); The samples were collected 7 days after the experiment, and the pathological examination of each lung tissue was as follows: 1: no cancer, mild inflammation, no clear puncture point; 2: adenocarcinoma; 3: adenocarcinoma, focal alveolar epithelial atypical hyperplasia; 4: no cancer, focal alveolar epithelial atypical hyperplasia; 5: adenocarcinoma;
[0064] Fig.14 Pathological staining results of test group 9 in experimental example 2 (10×10); samples were collected 7 days after the experiment, and the pathological examination of each lung tissue was as follows: 1: adenocarcinoma; 2: adenocarcinoma, diaphragmatic atrophy, fibrous tissue hyperplasia; 3: adenocarcinoma; 4: adenocarcinoma; 5: adenocarcinoma;
[0065] Fig.15 Pathological staining results of 10 lung tissues in the experimental group in Experimental Example 2 (10×10); samples were collected 7 days after the experiment, and pathological examination of each lung tissue was as follows: 1: no cancer; 2: adenocarcinoma; 3: adenocarcinoma; 4: adenocarcinoma; 5: adenocarcinoma, with tumor necrosis.
[0066] Specific embodiment
[0067] The present invention is further described in detail below in conjunction with specific embodiments. The given examples are only for illustrating the present invention, but not for limiting the scope of the present invention.
[0068] The experimental methods in the following examples are conventional methods unless otherwise specified. The medicinal materials, reagents, etc. used in the following examples are commercially available products unless otherwise specified.
[0069] The experimental materials and sources in the following examples are as follows:
[0070] Glucose: (≥99.5%), Sinopharm Chemical Reagent Co., Ltd., batch number: 20140821.
[0071] Acetic acid: (≥99.5%), Sinopharm Chemical Reagent Co., Ltd., batch number: 20160920.
[0072] Ethanol: (≥95%), Sinopharm Chemical Reagent Co., Ltd., batch number: 20200810.
[0073] Example 1 Composition of the present invention
[0074] Formula: Glucose 10g acetic acid 1mL;
[0075] Preparation method: Mix 10g glucose and mL acetic acid evenly and set aside.
[0076] Example 2 Composition of the present invention
[0077] Formula: Glucose 10g acetic acid 2mL;
[0078] Preparation method: Mix 10g glucose and 2mL acetic acid evenly and set aside.
[0079] Example 3 Composition of the present invention
[0080] Formula: Glucose 10g acetic acid 3mL;
[0081] Preparation method: Mix 10g glucose and 3mL acetic acid evenly and set aside.
[0082] Example 4 Composition of the present invention
[0083] Formula: Glucose 10g acetic acid 4mL;
[0084] Preparation method: Mix 10g glucose and 4mL acetic acid evenly and set aside.
[0085] Example 5 Composition of the present invention
[0086] Formula: Glucose 10g acetic acid 5mL;
[0087] Preparation method: Mix 10g glucose and 5mL acetic acid evenly and set aside.
[0088] Example 6 Composition of the present invention
[0089] Formula: Glucose 10g acetic acid 6mL;
[0090] Preparation method: Mix 10g glucose and 6mL acetic acid evenly and set aside.
[0091] Example 7 Composition of the present invention
[0092] Formula: Glucose 10g acetic acid 7mL;
[0093] Preparation method: Mix 10g glucose and 7mL acetic acid evenly and set aside.
[0094] Example 8 Composition of the present invention
[0095] Formula: Glucose 10g acetic acid 8mL;
[0096] Preparation method: Mix 10g glucose and 8mL acetic acid evenly and set aside.
[0097] Example 9 Composition of the present invention
[0098] Formula: Glucose 10g acetic acid 9mL;
[0099] Preparation method: Mix 10g glucose and 9mL acetic acid evenly and set aside.
[0100] Example 10 Composition of the present invention
[0101] Formula: Glucose 10g acetic acid 10mL;
[0102] Preparation method: Mix 10g glucose and 10mL acetic acid evenly and set aside.
[0103] Example 11 Composition of the present invention
[0104] Formula: Glucose 10g, acetic acid 1mL, ethanol 1mL
[0105] Preparation method: Mix 10 g of glucose, 1 mL of acetic acid and 1 mL of ethanol evenly and set aside.
[0106] Example 12 Composition of the present invention
[0107] Formula: Glucose 10g, acetic acid 2mL, ethanol 2mL
[0108] Preparation method: Mix 10 g of glucose, 2 mL of acetic acid and 2 mL of ethanol evenly and set aside.
[0109] Example 13 Composition of the present invention
[0110] Formula: Glucose 10g, acetic acid 3mL, ethanol 3mL
[0111] Preparation method: Mix 10 g of glucose, 3 mL of acetic acid and 3 mL of ethanol evenly and set aside.
[0112] Example 14 Composition of the present invention
[0113] Formula: Glucose 10g, acetic acid 4mL, ethanol 4mL
[0114] Preparation method: Mix 10 g of glucose, 4 mL of acetic acid and 4 mL of ethanol evenly and set aside.
[0115] Example 15 Composition of the present invention
[0116] Formula: Glucose 10g, acetic acid 5mL, ethanol 5mL
[0117] Preparation method: Mix 10 g of glucose, 5 mL of acetic acid and 5 mL of ethanol evenly and set aside.
[0118] Example 16 Composition of the present invention
[0119] Formula: Glucose 10g, acetic acid 6mL, ethanol 6mL
[0120] Preparation method: Mix 10 g of glucose, 6 mL of acetic acid and 6 mL of ethanol evenly and set aside.
[0121] Example 17 Composition of the present invention
[0122] Formula: Glucose 10g, acetic acid 7mL, ethanol 7mL
[0123] Preparation method: Mix 10 g of glucose, 7 mL of acetic acid and 7 mL of ethanol evenly and set aside.
[0124] Example 18 Composition of the present invention
[0125] Formula: Glucose 10g, acetic acid 8mL, ethanol 8mL
[0126] Preparation method: Mix 10 g of glucose, 8 mL of acetic acid and 8 mL of ethanol evenly and set aside.
[0127] Example 19 Composition of the present invention
[0128] Formula: Glucose 10g, acetic acid 9mL, ethanol 9mL
[0129] Preparation method: Mix 10 g of glucose, 9 mL of acetic acid and 9 mL of ethanol evenly and set aside.
[0130] Example 20 Composition of the present invention
[0131] Formula: Glucose 10g, acetic acid 10mL, ethanol 10mL
[0132] Preparation method: Mix 10 g of glucose, 10 mL of acetic acid and 10 mL of ethanol evenly and set aside.
[0133] Experimental Example 1 Study on the composition of the present invention inducing lung cancer in rats
[0134] 1. Experimental purpose:
[0135] The composition of the present invention was tested and verified to induce lung cancer in rat models at different time points.
[0136] 2. Materials and Methods
[0137] 2.1 Experimental Materials and Reagents
[0138] 2.1.1 Main experimental reagents:
[0139]
[0140] 2.1.2 Main experimental equipment:
[0141]
[0142]
[0143] 2.2 Experimental animals
[0144] Species & strain: SD rat;
[0145] Animal grade: SPF grade;
[0146] Gender: Male;
[0147] Source of experimental animals: Liaoning Changsheng Biotechnology Co., Ltd.
[0148] Age or weight: 200g±20g;
[0149] Quantity: 30 pcs;
[0150] 2.3 Experimental methods
[0151] 2.3.1 Animal husbandry:
[0152] The temperature of the breeding room is 18-22℃, the humidity is 40-70%, the ventilation frequency is not less than 20 times / h, no more than 6 animals are kept in each cage, and the light is 12 hours of light and dark alternation. The animals are given qualified mouse feed and are free to eat. The animals are given purified water, which is supplied by drinking bottles, and they can drink water freely.
[0153] 2.3.2 Induction injection:
[0154] The experimental animals were grouped and dosed as follows:
[0155] The animals were randomly divided into 5 groups according to their body weight, with 6 animals in each group. The inducer conditions and dosages of the animals in each group are shown in the following table:
[0156]
[0157]
[0158] Note: The preparation method of the inducer in the above table is: add 1g glucose to 0.375ml hydrochloric acid, heat at low temperature and stir until it becomes a colorless, transparent, viscous liquid.
[0159] Rats were anesthetized with isoflurane, and the hair and skin of the left armpit of the rat were shaved and prepared, which was disinfected with iodine. 50 μL of modeling drug was drawn with a microsyringe. The rat was placed in lateral position with the left side facing upward and the left forelimb naturally bent. The needle was inserted between the ribs behind the elbow joint of the left forelimb of the rat at an angle of 45° to the horizontal plane to a depth of 1 cm, which was enough to enter the lung. 50 μL of modeling drug was injected, and the formation of lung cancer model was detected at different time points.
[0160] 2.3.3 Pathological examination:
[0161] Rats were anesthetized and killed by intravenous injection of chloral hydrate, and the chest cavity was opened. The lesions at the drug administration site were observed according to the drug administration site in the lung, and the samples were fixed, dehydrated, embedded, sliced, spread, and baked in a programmed manner. The samples were dewaxed in xylene for 5 minutes × 3 times, 100% ethanol for 2 minutes × 2 times, rinsed with tap water for 2 minutes, stained with hematoxylin for 3 minutes, tap water for 2 minutes, differentiated with 1% hydrochloric acid alcohol solution for 2 seconds, rinsed with tap water for 2 minutes, blue solution for 1 second, tap water for 2 minutes, eosin staining for 10 seconds, dehydrated with 50% ethanol for 10 seconds, dehydrated with 70% ethanol for 10 seconds, anhydrous ethanol for 1 minute × 2 times, transparent in xylene for 3 minutes × 2 times, and sealed with neutral gum. Microscope photography and slide reading.
[0162] 2.4 Experimental Results
[0163] The results of HE pathological staining in each experimental group are as follows Figure 1 -to Figure 5 .
[0164] 3 Conclusion
[0165] This study shows that the glucose and saline in the control group 1 failed to induce cancer, and the saline and hydrochloric acid in the control group 2 were highly toxic and did not induce cancer in a short period of time. However, after the inducer was optimized, cancer was detected in the injection area of the experimental group on the 4th day, and pathological examinations on the 7th and 14th days further confirmed the effect of the inducer in inducing adenocarcinoma in the rat lungs. This proves that the inducer prepared in this way can induce lung cancer in rats in a short period of time.
[0166] Experimental Example 2 Study on the induction of canceration in rabbit lung tissue by the composition of the present invention
[0167] 1. Experimental purpose:
[0168] The composition of the present invention was tested and verified to induce lung cancer in experimental rabbit models at different time points.
[0169] 2. Materials and Methods
[0170] 2.1 Experimental Materials and Reagents
[0171] 2.1.1 Main experimental reagents:
[0172]
[0173] 2.1.2 Main experimental equipment:
[0174]
[0175]
[0176] 2.2 Experimental animals
[0177] Species & Strain: New Zealand White Rabbit;
[0178] Animal grade: SPF grade;
[0179] Gender: Male;
[0180] Source of experimental animals: China Food and Drug Inspection Institutes;
[0181] Age or weight: 1.8-2.2 kg;
[0182] Quantity: 50 pcs;
[0183] 2.3 Experimental methods
[0184] 2.3.1 Animal husbandry:
[0185] The temperature of the breeding room is 18-22℃, the humidity is 40-70%, the ventilation frequency is not less than 20 times / h, no more than 2 animals are kept in each cage, and the light is 12 hours of light and dark alternation. The animals are given qualified feed and are free to eat. The animals are given purified water, which is supplied by drinking bottles and free to drink water.
[0186] 2.3.2 Induction injection:
[0187] The model preparation method is as follows: The animals were randomly divided into 10 groups according to their body weight, with 5 animals in each group. The inducer conditions and dosages of the animals in each group are as follows:
[0188]
[0189]
[0190] The experimental rabbit was placed in a lateral position with the left side facing upward. The left armpit was shaved and the skin was prepared and disinfected with iodine. The ribs were counted from the lower edge of the ribs forward. The needle was inserted between the 7th and 8th ribs, 2 finger widths away from the spine. 300uL of modeling drug was drawn into a 1mL syringe. The needle was inserted to a depth of the entire syringe needle, about 2.5cm, and the drug was then injected into the lungs.
[0191] 2.3.3 Pathological examination:
[0192] The rabbits were anesthetized and killed by intravenous injection of chloral hydrate, and the chest cavity was opened. The lesions at the drug administration site were observed according to the drug administration site in the lung, and the samples were fixed, dehydrated, embedded, sliced, spread, and baked in a programmed manner. The samples were dewaxed in xylene for 5 minutes × 3 times, 100% ethanol for 2 minutes × 2 times, rinsed with tap water for 2 minutes, stained with hematoxylin for 3 minutes, tap water for 2 minutes, differentiated with 1% hydrochloric acid alcohol solution for 2 seconds, rinsed with tap water for 2 minutes, blue solution for 1 second, tap water for 2 minutes, eosin staining for 10 seconds, dehydrated with 50% ethanol for 10 seconds, dehydrated with 70% ethanol for 10 seconds, anhydrous ethanol for 1 minute × 2 times, transparent in xylene for 3 minutes × 2 times, and sealed with neutral gum. The slides were photographed under a microscope and read.
[0193] 2.4 Experimental Results
[0194] The results of HE pathological staining in each experimental group are as follows Figures 6 to 15 .
[0195] 3 Conclusion
[0196] This study shows that, except for the control group of experimental group 1, all other formulas can induce cancer within 7 days. Taking into account both safety and induction efficiency, the formula of experimental group 2 (normal saline and concentrated hydrochloric acid mixture (volume ratio 5:3)) and the formula of experimental group 9 (50% glucose injection and lactic acid mixture (volume ratio 10:1)) are the best. Adding glucose to the formula can effectively reduce the degree of local acute irritation and reduce the death of experimental animals.
Claims
1. A composition consisting of sugar and acid.
2. The composition according to claim 1, wherein The sugar is a polyhydroxy (2 or more) aldehyde or ketone compound, composed of carbon, hydrogen and oxygen, preferably glucose; Preferably, the acid is an organic acid or an inorganic acid; Preferably, the acid is 85% (mass percent concentration) phosphoric acid, 37% (mass percent concentration) hydrochloric acid, 99.5% (mass percent concentration) acetic acid or 85% (mass percent concentration) lactic acid; Preferably, the mass volume ratio between the sugar and the acid is 1:100-100:1 (g / mL), preferably 1:20-20:1 (g / mL), more preferably 1:0.375 (g / mL) or 5:1 (g / mL); preferably, the pH value of the composition is lower than 4, preferably lower than 3.22; Preferably, the composition is a food composition.
3. A composition consisting of sugar, acid and alcohol.
4. The composition according to claim 3, wherein The alcohol is ethanol; Preferably, the ratio between the sugar, acid and alcohol is 1:100:1-100:1:100 (g / mL / mL), preferably 1:20:1-20:1:20 (g / mL / mL), more preferably 10:5:5 (g / mL / mL); Preferably, the composition is a food composition.
5. Use of the composition according to any one of claims 1 to 4 in preparing an animal model.
6. The use according to claim 5, wherein The model animals used in the animal model include, but are not limited to, mammals, such as mice, rats, rabbits, dogs, monkeys, cats, chickens, pigs, etc.; Preferably, the animal model is administered by various routes such as feeding, gavage, intravenous drip, intravenous injection or skin penetration to the model animal; Preferably, the animal models include, but are not limited to, animal models of diabetes, various cancers, atherosclerosis and cardiovascular and cerebrovascular diseases caused by them and other diseases.
7. The use according to claim 5, wherein The animal model is used for screening drugs for preventing and / or treating cancer, diabetes, atherosclerosis and cardiovascular and cerebrovascular diseases caused by them and other diseases.
8. Use of an acid in preparing an animal model, preferably, the acid is an inorganic acid (such as hydrochloric acid) or an organic acid; Preferably, the acid is 13.88% (mass percent concentration) hydrochloric acid, 7.73% (mass percent concentration) lactic acid, 4.74-9.05% (mass percent concentration) acetic acid, 7.73% (mass percent concentration) phosphoric acid; Preferably, the pH of the acid is below 4, preferably below 3.
22.
9. The use according to claim 8, wherein The model animals used in the animal model include, but are not limited to, mammals, such as mice, rats, rabbits, dogs, monkeys, cats, chickens, pigs, etc.; Preferably, the animal model is administered by various routes such as feeding, gavage, intravenous drip, intravenous injection or skin penetration to the model animal; Preferably, the animal models include, but are not limited to, animal models of diabetes, various cancers, atherosclerosis and cardiovascular and cerebrovascular diseases caused by them and other diseases.
10. The use according to claim 8, wherein The animal model is used for screening drugs for preventing and / or treating cancer, diabetes, atherosclerosis and cardiovascular and cerebrovascular diseases caused by them and other diseases.
